Fig. 2From: Assessment of safety, efficacy, and dosimetry of a novel 18-kDa translocator protein ligand, [11C]CB184, in healthy human volunteersMean decay-corrected TACs of five brain regions after intravenous injection of [11C]CB184 into typical human subjects (a). Comparison of TACs in the frontal cortex for typical subjects and an atypical subject (b). Data for typical subjects represent the mean ± SD of four subjectsBack to article page